Sept 11 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results